Goldman Sachs Group Inc. Lowers Alnylam Pharmaceuticals Inc. (ALNY) Price Target to $34.00
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) had its target price dropped by equities research analysts at Goldman Sachs Group Inc. from $65.00 to $34.00 in a research note issued to investors on Thursday. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s price objective would indicate a potential downside of 51.64% from the stock’s current price.
A number of other equities research analysts have also commented on the company. Stifel Nicolaus decreased their price objective on Alnylam Pharmaceuticals from $68.00 to $36.00 and set a “hold” rating for the company in a research report on Thursday. Jefferies Group decreased their price objective on Alnylam Pharmaceuticals from $86.00 to $58.00 and set a “buy” rating for the company in a research report on Thursday. Credit Suisse Group AG raised their price objective on Alnylam Pharmaceuticals from $50.00 to $145.00 and gave the stock an “outperform” rating in a research report on Thursday. Needham & Company LLC lowered Alnylam Pharmaceuticals to a “buy” rating and decreased their price objective for the stock from $152.00 to $137.00 in a research report on Thursday. Finally, Chardan Capital raised their price objective on Alnylam Pharmaceuticals from $77.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday. Seven equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $94.31.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 46.93% during mid-day trading on Thursday, reaching $37.31. 7,808,155 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a 1-year low of $35.31 and a 1-year high of $110.75. The firm has a 50-day moving average price of $72.86 and a 200-day moving average price of $66.46. The company’s market capitalization is $3.20 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The business earned $8.70 million during the quarter, compared to analyst estimates of $8.09 million. During the same quarter last year, the company posted ($0.85) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up .2% on a year-over-year basis. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post ($4.64) earnings per share for the current fiscal year.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the transaction, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at approximately $9,604,200.85. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 4.00% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP increased its position in shares of Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock valued at $749,826,000 after buying an additional 1,288,123 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 5,385,509 shares of the biopharmaceutical company’s stock valued at $298,843,000 after buying an additional 182,614 shares in the last quarter. Baillie Gifford & Co. increased its position in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Baillie Gifford & Co. now owns 3,390,252 shares of the biopharmaceutical company’s stock valued at $188,125,000 after buying an additional 10,317 shares in the last quarter. Dodge & Cox acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $139,650,000. Finally, State Street Corp raised its stake in shares of Alnylam Pharmaceuticals by 13.4% in the second quarter. State Street Corp now owns 2,195,504 shares of the biopharmaceutical company’s stock valued at $121,832,000 after buying an additional 258,984 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.